Mercier Johanna

Mercier Johanna, Chief Communications and Corporate Affairs Officer at Gilead Sciences (GILD), has been a consistent seller of company stock over the past year, with zero open-market purchases across her 67 total transactions. Her Form 4 filings show $17.4 million in total sales value across two companies, with the overwhelming majority concentrated in GILD. The selling pattern is steady and recurring—monthly open-market sales (code S) appear on or around the 15th of each month, including $422,880 on April 15, 2026, $432,690 on March 16, 2026, and a cluster of four sales on May 15, 2026 totaling roughly $3.7 million. Her largest single transaction was a $2.84 million sale on February 17, 2026, followed by another $1.46 million sale the same day. The transaction structure reveals a mechanical pattern typical of an executive compensation cycle rather than discretionary timing. Several sales are paired with option exercises (code M) at zero value, including a $1.67 million exercise on both February 17 and May 15, 2026, suggesting she is exercising vested options and immediately selling the shares. Additionally, significant tax-withholding sales (code F) appear after equity grants—$3.55 million on February 3, 2026, and $477,769 on March 10, 2026—which are automatic dispositions to cover tax obligations. The only non-GILD activity involves Neurocrine Biosciences (NBIX), where she received a grant (code A) on May 27, 2026, and exercised options on May 21, 2026, both at zero value with no corresponding sale. The data shows a clear one-directional bias: 13 recent sales totaling over $17 million, no purchases, and no acquisitions beyond compensation grants and option exercises. The most recent transaction, a $389,758 sale on July 15, 2026, continues the established cadence. While the volume is substantial, the pattern—monthly sales, paired exercises, and tax-related dispositions—aligns with routine portfolio management rather than concentrated or opportunistic selling. Her holdings in NBIX appear to be accumulating through equity compensation without any corresponding sales, though the dollar value of those positions is not disclosed in the recent filings.